Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Opinion: value of MRD as an endpoint in hem-onc clinical trials

Robert Hills • 5 Oct 2018
ESH MM 2018
General

Measurable residual disease (MRD) is a hot topic, with it’s full potential still to be fully realized. We spoke to Robert Hills from the University of Oxford, Oxford, UK, about his thoughts on the value of MRD as an endpoint in clinical trials in the hemato-oncology field. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Robert Hills

2:05
UK NCRI AML17 trial update: everolimus addition for consolidation
Robert Hills • 5 Oct 2018
2:24
Judging the value of a clinical trial in hem-onc
Robert Hills • 5 Oct 2018

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals